$245.73 Million in Sales Expected for LivaNova PLC (NASDAQ:LIVN) This Quarter

Brokerages expect LivaNova PLC (NASDAQ:LIVN) to post $245.73 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for LivaNova’s earnings, with the lowest sales estimate coming in at $236.40 million and the highest estimate coming in at $251.90 million. LivaNova posted sales of $240.10 million in the same quarter last year, which suggests a positive year over year growth rate of 2.3%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 4th.

According to Zacks, analysts expect that LivaNova will report full year sales of $1.02 billion for the current year, with estimates ranging from $1.01 billion to $1.02 billion. For the next fiscal year, analysts forecast that the company will post sales of $1.05 billion, with estimates ranging from $1.03 billion to $1.07 billion. Zacks’ sales averages are an average based on a survey of analysts that cover LivaNova.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, July 28th. The company reported $0.52 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.19. The company had revenue of $264.50 million for the quarter, compared to analysts’ expectations of $241.73 million. LivaNova had a positive return on equity of 8.44% and a negative net margin of 37.15%.

A number of analysts recently weighed in on LIVN shares. Zacks Investment Research upgraded LivaNova from a “sell” rating to a “hold” rating in a report on Wednesday, August 4th. Robert W. Baird raised their price objective on LivaNova from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 17th. They noted that the move was a valuation call. Piper Sandler lowered their price objective on LivaNova from $99.00 to $98.00 and set an “overweight” rating for the company in a research report on Tuesday, June 1st. Finally, Needham & Company LLC lifted their target price on LivaNova from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, August 20th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $101.00.

NASDAQ LIVN traded up $0.83 on Friday, hitting $84.43. The company’s stock had a trading volume of 3,829 shares, compared to its average volume of 401,879. The company’s 50-day moving average is $82.23 and its 200 day moving average is $81.35. The firm has a market cap of $4.14 billion, a PE ratio of -10.73 and a beta of 0.90. LivaNova has a 1-year low of $41.07 and a 1-year high of $90.25. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 0.41.

In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 1st. The stock was sold at an average price of $82.40, for a total value of $82,400.00. Following the transaction, the director now owns 31,630 shares in the company, valued at approximately $2,606,312. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.37% of the company’s stock.

A number of hedge funds have recently modified their holdings of LIVN. Point72 Hong Kong Ltd bought a new stake in shares of LivaNova during the 1st quarter valued at $27,000. IndexIQ Advisors LLC purchased a new position in shares of LivaNova during the first quarter worth about $29,000. Itau Unibanco Holding S.A. bought a new position in shares of LivaNova in the second quarter worth approximately $45,000. Meeder Asset Management Inc. lifted its holdings in shares of LivaNova by 32.6% in the 1st quarter. Meeder Asset Management Inc. now owns 794 shares of the company’s stock worth $59,000 after acquiring an additional 195 shares during the last quarter. Finally, Captrust Financial Advisors boosted its position in LivaNova by 1,066.3% during the first quarter. Captrust Financial Advisors now owns 1,108 shares of the company’s stock valued at $82,000 after buying an additional 1,013 shares during the period. 94.97% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products.

Recommended Story: Trade War

Get a free copy of the Zacks research report on LivaNova (LIVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.